Trials / Completed
CompletedNCT05743764
HU007 in Patients with Dry Eye Syndrome
A Multicenter, Randomized, Double Blind, Restasis®-Controlled Non-inferiority, Moisview® Eye Drops Controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 328 (actual)
- Sponsor
- Huons Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops Controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HU007 | cyclosporine 0.02%, trehalose 3% |
| DRUG | Restasis | cyclosporine 0.05% |
| DRUG | Moisview Eye drop | trehalose 3% |
Timeline
- Start date
- 2023-03-23
- Primary completion
- 2024-02-14
- Completion
- 2024-02-14
- First posted
- 2023-02-24
- Last updated
- 2024-09-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05743764. Inclusion in this directory is not an endorsement.